Psychosis associated with interferon alfa therapy for chronic XXXX .

@entity1 @entity2167 @entity1956 @entity146 @entity716 @entity3027
OBJECTIVE: To report a case of persistent @entity716 that developed during interferon alfa ( @entity3027 ) therapy for chronic @entity1956 . CASE SUMMARY: A 26-year-old @entity1 who was diagnosed with active chronic @entity1956 began treatment with @entity3027 . Five months after initiation of therapy, he developed @entity716 with prominent persecutory delusions and @entity2167 . Despite discontinuation of @entity3027 therapy and addition of antipsychotic drug treatment, only partial recovery from @entity716 was observed after 4 months of hospitalization. DISCUSSION: Unlike many previously reported cases, this @entity1 showed only partial recovery from @entity716 , despite the discontinuation of IFN therapy. Except for receiving a relatively high dose of @entity3027 (10 million units 3 times/wk), the @entity1 did not have any previously proposed risk factors for developing @entity146 adverse effects. The Naranjo probability scale indicates a probable relationship between the @entity716 and IFN therapy. CONCLUSIONS: Despite its rare occurrence, @entity716 can emerge during @entity3027 therapy. This adverse effect may persist for several months, even after appropriate medical management. @entity3027 should be used with careful monitoring of @entity1 ' @entity146 status during all stages of therapy.
